Breaking News

TrumpRx arrives. Will it keep drug prices down?

February 6, 2026
rose-b-avatar-teal
Disability in Health Care Reporting Fellow

Maybe it's just that I haven't eaten lunch yet as I write this Thursday afternoon, but Sarah Todd's story on the ties between Big Tobacco and Big Food has such a delightful opening. Scroll down to read.

DRUGS

TrumpRx arrives

Andrew Harnik/Getty Images

President Trump's new platform aimed at lowering prescription drug prices launched yesterday, after months of fanfare. Will it actually affect affordability? Depends on who you ask.

The website, which uses technology from health care company GoodRx, displays the cash prices — that is, the prices available when paying without insurance — for certain drugs. It will not sell medications directly, but direct people elsewhere.

The direct-pay model has been gaining traction in the pharma industry for years, spurred in part by Eli Lilly and Novo Nordisk and their GLP-1 obesity drugs. But buying drugs directly may end up being more expensive than using insurance in the long run, drug pricing experts say.

My colleagues have all of the TrumpRx details — the where, what, who, when, why, and how expensive GLP-1's will be. Read more.


TRANS

More hospitals end gender-affirming care for minors

In the last year, more than 40 hospitals and health systems have paused or ended gender-affirming care for young trans people, a number that has accelerated in recent weeks in the wake of federal rules proposed in December that would withhold Medicare and Medicaid funding from clinics that continue pediatric care for transgender children and teenagers.

Hospitals are stopping services even though the proposed CMS rules aren't final, and Trump's initial executive order targeting this type of care has been challenged in court. Backed by findings from major medical organizations, many clinics have provided estrogen, testosterone, and puberty blockers to trans adolescents for years. Major medical organizations have historically recommended that surgeries be offered to transgender minors on a case-by-case basis, but few providers have ever performed them.

Important story from STAT's Theresa Gaffney. Read more.


TELEHEALTH

Be wary of multi-cancer early detection tests

If you watch the Super Bowl this Sunday, you might catch a glimpse of Hims' latest prime-time commercial: a minute-long slot featuring Galleri, a multi-cancer early detection test.

The test is one of several that haven't yet been approved by the Food and Drug Administration. But telehealth platforms are still permitted to market them — a move that some cancer and health policy experts warn could give patients false reassurance before any evidence of benefit. Grail, Galleri's developer, has faced many hurdles as it worked to validate its blood-based test for detecting dozens of tumor types.

If you get a positive test result, it's often right. But a negative result shouldn't elicit a sigh of relief — in one study, Galleri missed more cancers than it detected. There are more risks, still.

As usual, STAT's Katie Palmer has you covered on all things telehealth. Read the story.



BIG FOOD

The fight against ultra-processed food turns to the anti-tobacco playbook

bigfood-1-1600x900

Camille MacMillin/STAT

Critics are intensifying a public relations war against ultra-processed food by highlighting its history with the widely distrusted tobacco industry — and exploring how strategies against Big Tobacco might be applied to food.

Researchers, nutrition advocates and politicians across the political spectrum say ultra-processed food manufacturers have perverted the brain's built-in reward system, wreaking havoc on Americans' health through a parade of Chips Ahoy! and Cheetos. Health secretary Robert F. Kennedy Jr. has even argued that the "thousands of scientists" that made tobacco addictive have moved to do the same for food.

The food industry rejects this association and has responded with a new seven-figure ad campaign that emphasizes the manufacturing jobs it creates and the benefits of "everyday essentials that are convenient, affordable, and above all, safe."

How real is this comparison between Big Tobacco and Big Food? Where does it fall short? Read this excellent story from STAT's Sarah Todd.


PURPLE (G)RAIN

What is a 'natural' dye, anyway?

The Food and Drug Administration yesterday announced that it's making it easier for companies to transition from artificial, petroleum-based colors to dyes derived from natural sources. Whereas the FDA's previous definition of "artificial color" meant that the color did not naturally occur in that food (for instance, a dye making butter more yellow), the new FDA labeling approach focuses on whether a dye is derived from natural sources or from petroleum-based sources (i.e., whether that color comes from Yellow No. 5 or annatto extract.)

The Environmental Working Group, an advocacy group, slammed the announcement as a "retreat" from health secretary Kennedy's promise to ban synthetic food dyes altogether.

As STAT's friendly neighborhood PhD chemist, I am here to remind you that everything is chemicals no matter where it comes from. "Natural" vanilla includes vanillin made from tree pulp waste, and just because a dye is "natural" doesn't mean it's necessarily squeezed from the teat of a beet. The FDA's new working definition of "natural" dyes includes dyes that are manufactured via fermentation from yeast, algae, or fungi; mixed or reacted with other chemicals, or extracted from plants bred to maximize color production. — Brittany Trang 


FIRST OPINION

Former FDA head: HHS leadership is undermining evidence-based policy

Pediatric cardiologist Kirk Milhoan, the new chair of the Centers for Disease Control and Prevention's Advisory Panel on Vaccination Practices, recently said the polio vaccine may not be necessary, and that he trusted his own observations regarding vaccines over established science.

Privileging individual insights over collective wisdom undermines the work to keep a society safe and healthy, Robert M. Califf, M.D., the former commissioner of the Food and Drug Administration, argues in a new First Opinion. "Even a professional's naïve analysis of aggregate data can be insightful, but also can be profoundly misleading."

Health care must be built on a collective foundation of evidence and expertise. "When it comes to medical and public health interventions, we ignore evidence and expertise at our peril," said Califf, now an instructor at the Duke University School of Medicine. Read more.


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

What we're reading

  • Why are some women training for pregnancy like it's a marathon? WIRED

  • Some Public Health Service officers deployed in detention centers suffer 'moral distress', NPR
  • These patients saw what comes after death. Should we believe them?, The Washington Post
  • Measles outbreak in Mexico prompts health alert in World Cup host Jalisco, AP
  • Unlicensed weight-loss drugs marketed on social media as 'prizes', The Guardian


Thanks for reading! 
Rose

Timmy


Enjoying Morning Rounds? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2026, All Rights Reserved.

No comments